Literature DB >> 33118928

Selective serotonin reuptake inhibitor use is associated with worse sleep-related breathing disturbances in individuals with depressive disorders and sleep complaints: a retrospective study.

Rébecca Robillard1,2, Mysa Saad1,3, Laura B Ray1, Brad BuJáki1,4, Alan Douglass1,4,5, Elliott K Lee1,4,5, Louis Soucy4,5, Naomi Spitale1,4, Joseph De Koninck1,2, Tetyana Kendzerska3,6.   

Abstract

STUDY
OBJECTIVES: The effects of serotonergic agents on respiration neuromodulation may vary according to differences in the serotonin system, such as those linked to depression. This study investigated how sleep-related respiratory disturbances relate to depression and the use of medications commonly prescribed for depression.
METHODS: Retrospective polysomnography was collated for all 363 individuals who met selection criteria out of 2,528 consecutive individuals referred to a specialized sleep clinic (Ottawa, Canada) between 2006 and 2016. The apnea-hypopnea index (AHI), oxygen saturation nadir, and oxygen desaturation index during REM and NREM sleep were analyzed using mixed analyses of covariance comparing 3 main groups: (1) medicated individuals with depressive disorders (antidepressant group; subdivided into the selective serotonin reuptake inhibitor and norepinephrine-dopamine reuptake inhibitor subgroups), (2) non-medicated individuals with depressive disorders (non-medicated group), and (3) mentally healthy control patients (control group).
RESULTS: Individuals with depressive disorders (on antidepressants or not) had significantly higher AHIs compared to control patients (both P ≤ .007). The antidepressant group had a lower NREM sleep oxygen saturation nadir and a higher NREM sleep oxygen desaturation index than the control and non-medicated groups (all P ≤ .009). Within individuals with depressive disorders, independent of depression severity, the selective serotonin reuptake inhibitor group had a lower oxygen saturation nadir and a higher oxygen desaturation index during NREM sleep than the norepinephrine-dopamine reuptake inhibitor (both P ≤ .045) and non-medicated groups (both P < .001) and a higher NREM sleep AHI than the non-medicated group (P = .014).
CONCLUSIONS: These findings suggest that the use of selective serotonin reuptake inhibitors may be associated with impaired breathing and worse nocturnal oxygen saturation in individuals with depressive disorders and sleep complaints, but this needs to be confirmed by prospective studies.
© 2021 American Academy of Sleep Medicine.

Entities:  

Keywords:  OSA; antidepressants; depression; selective serotonin reuptake inhibitor; sleep-related breathing disturbances

Mesh:

Substances:

Year:  2021        PMID: 33118928      PMCID: PMC7927326          DOI: 10.5664/jcsm.8942

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  44 in total

1.  Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence.

Authors:  Colette B Raymond; Steven G Morgan; Patricia A Caetano
Journal:  Psychiatr Serv       Date:  2007-01       Impact factor: 3.084

2.  Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004.

Authors:  Gianluca Trifirò; Corrado Barbui; Edoardo Spina; Salvatore Moretti; Michele Tari; Marianna Alacqua; Achille P Caputi; Vincenzo Arcoraci
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-05       Impact factor: 2.890

Review 3.  The visual scoring of sleep in adults.

Authors:  Michael H Silber; Sonia Ancoli-Israel; Michael H Bonnet; Sudhansu Chokroverty; Madeleine M Grigg-Damberger; Max Hirshkowitz; Sheldon Kapen; Sharon A Keenan; Meir H Kryger; Thomas Penzel; Mark R Pressman; Conrad Iber
Journal:  J Clin Sleep Med       Date:  2007-03-15       Impact factor: 4.062

4.  Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea.

Authors:  R B Berry; E M Yamaura; K Gill; C Reist
Journal:  Sleep       Date:  1999-12-15       Impact factor: 5.849

5.  Letter: Total and free plasma-tryptophan concentration and oral contraception.

Authors:  A Coppen; E Eccleston; I Craft; P Bye
Journal:  Lancet       Date:  1973-12-29       Impact factor: 79.321

6.  [Studies on the respiratory control mechanism of medullary raphe nuclei and their serotonergic system].

Authors:  K Kumaido
Journal:  No To Shinkei       Date:  1988-10

Review 7.  Effects of psychiatric medications on sleep and sleep disorders.

Authors:  Nicholas A DeMartinis; Andrew Winokur
Journal:  CNS Neurol Disord Drug Targets       Date:  2007-02       Impact factor: 4.388

Review 8.  Serotonin-1A receptor imaging in recurrent depression: replication and literature review.

Authors:  Wayne C Drevets; Michael E Thase; Eydie L Moses-Kolko; Julie Price; Ellen Frank; David J Kupfer; Chester Mathis
Journal:  Nucl Med Biol       Date:  2007-10       Impact factor: 2.408

9.  Serotonin targets inhibitory synapses to induce modulation of network functions.

Authors:  Till Manzke; Mathias Dutschmann; Gerald Schlaf; Michael Mörschel; Uwe R Koch; Evgeni Ponimaskin; Olivier Bidon; Peter M Lalley; Diethelm W Richter
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-09-12       Impact factor: 6.237

10.  The effect of sex and age on the comorbidity burden of OSA: an observational analysis from a large nationwide US health claims database.

Authors:  Babak Mokhlesi; Sandra A Ham; David Gozal
Journal:  Eur Respir J       Date:  2016-01-21       Impact factor: 16.671

View more
  2 in total

1.  The effect of brain serotonin deficiency on breathing is magnified by age.

Authors:  Huy Pho; Mateus R Amorim; Qingchao Qiu; Mi-Kyung Shin; Lenise J Kim; Frederick Anokye-Danso; Jonathan J Jun; Rexford S Ahima; Luiz G S Branco; Donald M Kuhn; Jason H Mateika; Vsevolod Y Polotsky
Journal:  Physiol Rep       Date:  2022-05

Review 2.  The Proposition for Bipolar Depression Forecasting Based on Wearable Data Collection.

Authors:  Pavel Llamocca; Victoria López; Milena Čukić
Journal:  Front Physiol       Date:  2022-01-25       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.